JEIL PHARMACEUTICAL CO., LTD.
🇰🇷South Korea
Shionogi's Antibiotic Fetroja Receives Marketing Approval in South Korea for Drug-Resistant Infections
• JEIL Pharmaceutical has secured regulatory approval in South Korea for Fetroja (cefiderocol), a novel siderophore cephalosporin antibiotic targeting carbapenem-resistant gram-negative bacterial infections.
• The approval is based on three global clinical trials, including studies in complicated urinary tract infections, carbapenem-resistant infections, and nosocomial pneumonia.
• This development addresses the growing threat of antimicrobial resistance (AMR), which is projected to cause over 10 million deaths annually by 2050 without proper intervention.
© Copyright 2025. All Rights Reserved by MedPath